Rigel Pharmaceuticals (RIGL) Short-term Investments (2010 - 2026)

Rigel Pharmaceuticals' Short-term Investments history runs 17 years deep, the most recent figure standing at $122.3 million for Q1 2026.

• In Q1 2026, Short-term Investments rose 289.76% year-over-year to $122.3 million; the TTM figure through Mar 2026 stood at $122.3 million (up 289.76% YoY), while the FY2025 annual figure was $114.4 million, up 455.89% from the prior year.
• Short-term Investments for Q1 2026 stood at $122.3 million, up from $114.4 million in the prior quarter.
• The five-year high for Short-term Investments was $122.3 million in Q1 2026, with the low at $9.4 million in Q3 2024.
• The 5-year median for Short-term Investments is $31.4 million (2025), against an average of $46.1 million.
• The sharpest annual moves came in 2023 and 2025: Short-term Investments tumbled 77.82% in 2023, then soared 840.45% in 2025.
• Rigel Pharmaceuticals' Short-term Investments stood at $33.7 million in 2022, then declined by 28.45% to $24.1 million in 2023, then decreased by 14.79% to $20.6 million in 2024, then jumped by 455.89% to $114.4 million in 2025, then advanced by 6.91% to $122.3 million in 2026.
• Business Quant data shows RIGL's Short-term Investments at $122.3 million in Q1 2026, $114.4 million in Q4 2025, and $88.6 million in Q3 2025.